The Highwire interview: Del Bigtree on Cannabis Science for Autism
In autism, major protective brain mechanisms become interrupted and neuroinflammation emerges. A variety of toxins are responsible for the consequential great demand for neuronal protection. This is where cannabis science comes in to play. And guess what? It’s backed by a lot of solid research. I can vouch for this: I’ve personally gathered cannabis papers for autism in the original Michigan petition 3 years ago and helped support 4 states’ petition as well. It’s a banker’s box full of the finest research papers.
Cannabis programs are implemented in 58% of all states in the United States, yet the federal government says it has no medicinal value and classifies it as dangerous as heroin (or natural peyote). What evidence is being defended to keep it that way? Congressional members are sticking their necks out to make sure individual states are not targeted by Jeff Sessions and the Feds.
Why is the FDA approving cannabis-like pharmaceuticals? When we dive into the more than 35,000 scientific articles that are available in regards to cannabis, we can clearly see that the current main stream narrative on its implementation in autism and other medical conditions is flawed. In a big way too.
Del wanted to get to the bottom of cannabis science for autism. He invited me to discuss the current status quo. Autism is just one of many conditions that respond to cannabis, with a safety profile that justifies de-scheduling on a federal level completely. The autism cannabis science we will present is just the tip of the iceberg. Cannabis is already heavily studied in other countries such as Israel. We will discuss some results of human trials and take a deeper look on the federal fraud of prohibition.